The estimated Net Worth of Romulus K Brazzell is at least $605 Tysiąc dollars as of 26 June 2024. Romulus Brazzell owns over 5,489 units of Kala Bio stock worth over $505,572 and over the last 7 years Romulus sold KALA stock worth over $99,133.
Sign up
Romulus Brazzell KALA stock SEC Form 4 insiders trading
Romulus has made over 11 trades of the Kala Bio stock since 2017, according to the Form 4 filled with the SEC. Most recently Romulus sold 5,489 units of KALA stock worth $26,073 on 26 June 2024.
The largest trade Romulus's ever made was exercising 108,725 units of Kala Bio stock on 11 August 2017 worth over $178,309. On average, Romulus trades about 9,923 units every 120 days since 2017. As of 26 June 2024 Romulus still owns at least 83,982 units of Kala Bio stock.
You can see the complete history of Romulus Brazzell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Romulus Brazzell's mailing address?
Romulus's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.
Insiders trading at Kala Bio
Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... oraz Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.
What does Kala Bio do?
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
What does Kala Bio's logo look like?
Complete history of Romulus Brazzell stock trades at Kala Bio
Kala Bio executives and stock owners
Kala Bio executives and other stock owners filed with the SEC include:
-
Mark Iwicki,
Chairman of the Board, President, Chief Executive Officer -
Todd Bazemore,
Chief Operating Officer -
Eric Trachtenberg,
Chief Compliance Officer, General Counsel, Secretary -
Kim Brazzell,
Chief Medical Officer -
Mark T. Iwicki,
Chairman & CEO -
Dr. Kim Brazzell Ph.D.,
Head of R&D and Chief Medical Officer -
Hongming Chen,
Chief Scientific Officer -
Todd Bazemore,
Pres & COO -
Andrew Koven,
Lead Independent Director -
Rajeev Shah,
Independent Director -
Gregory Perry,
Independent Director -
Robert Paull,
Independent Director -
Howard Rosen,
Independent Director -
Gregory Grunberg,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
Mary Reumuth,
Chief Financial Officer, Treasurer -
James Patnoe,
Sr. VP of Market Access, Commercial Operations & Pricing -
Vincent Kosewski,
Sr. VP of Manufacturing & Supply Chain Management -
Michele LaRussa,
Sr. VP of Regulatory Affairs & Quality Assurance -
Kathleen McCann Kline,
Sr. VP of Marketing -
Eric L. Trachtenberg,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Jill S. Steier,
Exec. Director of Investor Relations & Corp. Communications -
Mary Reumuth CPA, CPA,
CFO & Treasurer -
Dr. Justin Hanes Ph.D.,
Founder & Chair of the Scientific Advisory Board -
Capital Partners Ii, Llcenr...,
-
Harbor Master Investors (Ca...,
10% owner -
Associates, L.L.C.Caxton Co...,
-
Paulina Hill,
Director -
Advisors Llc Orbi Med Capit...,
-
Capital Management, L.P.Ra ...,
-
Robert I Tepper,
Director -
Robert Langer,
Director -
Advisors Llc Orbi Med Capit...,
-
Michele La Russa,
Sr. VP, Regulatory and Quality -
C. Daniel Myers,
-
Marjan Farid,
-
Capital Management, L.P.Ra ...,
-
Romulus K Brazzell,
SEE REMARKS -
Mark S. Blumenkranz,
-
Darius Kharabi,
CHIEF BUSINESS OFFICER